- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03244319
Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)
December 27, 2019 updated by: Yonsei University
- objectives: The primary aim of ENAVLE is to explore the efficacy of edoxaban in patients with post mitral valve repair or bioprosthetic valve implantation
- Primary / Secondary Endpoint
1) Efficacy Endpoint Evaluation: Occurrence of thromboembolic events and any thrombus at repaired ring or bioprosthetic valves detected by follow up echocardiography or 3D CT scan
2) Safety Endpoint Evaluation
- Dysfunction of treated valve caused by thrombosis on echocardiography or 3D CT scan
- Major or minor bleeding described in safety outcomes
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is an open labeled, parallel group, and randomization study.
At 7 days after mitral valve repair, bioprosthetic MV or AV replacement surgery, warfarin or edoxaban will be started per oral route.
All study patients started to receive bridging therapy with parenteral anti-coagulant (UFH) according to local practice before switching to warfarin or edoxaban.
Among patients who take warfarin, international normalized ratio will be used to monitor the effectiveness of the anticoagulant warfarin as usual daily practice.
All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3).
Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd ( creatinine clearance 30-49ml/min, body weight <60kg or concomitant use of certain P-glycoprotein inhibitors).
Both drugs will be maintained for 3 months.
During study period, all patients will be carefully monitored for thromboembolic events including valve dysfunction, and stroke or bleeding complication.
At 3 months after surgery, 3 dimensional CT scan and echocardiography will be performed for detecting valvular dysfunction, any thrombus or bleeding in heart & lung.
Study Type
Interventional
Enrollment (Actual)
220
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 03722
- Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients aged 20-85 years with
- MV repair or Bioprosthetic MV or AV replacement
- Patients with written informed consent
Exclusion Criteria:
- Previous mechanical prosthetic heart valve replacement
- Patients who underwent TAVI
- Concomitant bioprosthetic valve replacement of mechanical tricuspid or pulmonary replacement at the time of the index valve replacement surgery
- Clinically relevant paravalvular leaks
- Previous history of endocarditis
- Complex congenital heart abnormality
- Acute coronary syndrome within one month
- Uncontrolled hypertension
- Previous history of hemorrhagic stroke
- At high risk for bleeding
- Active hepatitis or liver dysfunction (AST/ALT> 3times of upper normal limits)
- Creatinine clearance < 30ml/min
- Patients with a clear indication for long-term dual antiplatelet therapy
- Malignancy or radiation therapy within one month
- Treatment with selected drugs that my interact with edoxaban (specific P-gp inhibitors, ie. verapamil, quinidine; the short-term use of azithromycin, clarithromycin, erythromycin, oral itraconazole, oral ketoconazole)
- At of pregnancy or breastfeeding
- Known allergy to warfarin or edoxaban
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Warfarin
|
All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3).
Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
parenteral anti-coagulant (UFH)
|
Experimental: Edoxaban
|
Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd (creatinine clearance 30-49ml/min, body weight <60kg or concomitant use of certain P-glycoprotein inhibitors).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of thromboembolic event
Time Frame: 12 weeks
|
Occurrence of thromboembolic events and any thrombus at repaired ring or bioprosthetic valves detected by follow up echocardiography or 3D CT scan
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dysfunction of treated valve
Time Frame: 12 weeks
|
Dysfunction of treated valve caused by thrombosis on echocardiography or 3D CT scan
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2017
Primary Completion (Actual)
September 30, 2019
Study Completion (Actual)
September 30, 2019
Study Registration Dates
First Submitted
August 6, 2017
First Submitted That Met QC Criteria
August 8, 2017
First Posted (Actual)
August 9, 2017
Study Record Updates
Last Update Posted (Actual)
January 2, 2020
Last Update Submitted That Met QC Criteria
December 27, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4-2017-0506
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MV(Mitral Valve) Repair
-
Abbott Medical DevicesCompletedMitral Valve (MV) RegurgitationGermany
-
Tehran University of Medical SciencesUnknown
-
Edwards LifesciencesActive, not recruitingMitral Regurgitation | Mitral Insufficiency | Mitral Repair | Mitral Valve | Annuloplasty | Edwards CardiobandSwitzerland, Germany, Italy
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingMitral Regurgitation | Surgery | Cardiac Valve Disease | Mitral Valve Disease | Mitral Valve Surgery | Mitral Valve RepairNetherlands
-
CoreMedic GmbHMeditrial Europe Ltd.Active, not recruitingMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve RepairLithuania
-
Heinrich-Heine University, DuesseldorfCompletedMitral Regurgitation | Local Anaesthesia | Percutaneous Repair
-
Medical University of ViennaNot yet recruitingMitral Regurgitation | ATTR-Cardiomyopathy | Edge-to-Edge Mitral Valve Repair
-
Konkuk University Medical CenterCompletedMitral Valve Repair SurgeryKorea, Republic of
-
Abbott Medical DevicesActive, not recruitingMitral Valve Disease | Damaged Mitral Valve | Malfunctioning Mitral Heart Valve | Mitral Valve ReplacementUnited States
-
University Hospital, Basel, SwitzerlandRecruitingMitral Valve Disease | Mitral Valve SurgerySwitzerland
Clinical Trials on Edoxaban
-
Portola PharmaceuticalsCompleted
-
Daiichi Sankyo, Inc.The TIMI Study GroupCompletedStroke | Embolism | Atrial FibrillationUnited States, Australia, France, Italy, Poland, Taiwan, Ukraine, United Kingdom, China, Belgium, Germany, Spain, Argentina, Colombia, Israel, Mexico, Portugal, Bulgaria, India, Romania, Russian Federation, Serbia, South Africa, Turkey, Korea, Republic of and more
-
Daiichi Sankyo, Inc.CompletedDeep Vein Thrombosis | Venous ThromboembolismSpain, United States, United Kingdom, India, France, Canada, Italy, Lebanon, Turkey
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
Montreal Heart InstituteServierActive, not recruitingValvular Heart Disease | Atrial Fibrillation and FlutterCanada
-
University of AlbertaRecruitingIschemic Stroke | Atrial Fibrillation | Hemorrhagic Transformation StrokeCanada
-
Takeshi MorimotoCompletedNeoplasms | Venous Thrombosis | AnticoagulantJapan
-
Asan Medical CenterSamsung Medical Center; Pusan National University Hospital; Chonnam National... and other collaboratorsRecruitingAtrial Fibrillation | Acute Ischemic Stroke | Anticoagulant | Coronary Artery Atherosclerosis | Intracranial Atherosclerosis | Extracranial Atherosclerosis | Antiplatelet | Peripheral Artery StenosisKorea, Republic of
-
Daiichi Sankyo, Inc.Completed
-
Turku University HospitalHelsinki University Central HospitalCompletedBlood Coagulation DisorderFinland